Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study
-
Published:2023-12
Issue:6
Volume:8
Page:102068
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Jung H.A.,
Park S.,
Lee S.-H.,
Ahn J.S.,
Ahn M.-J.,
Sun J.-M.ORCID
Subject
Cancer Research,Oncology
Reference22 articles.
1. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial;Wu;Lancet Oncol,2017
2. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations;Mok;J Clin Oncol,2018
3. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial;Ellis;Lancet Oncol,2014
4. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial;Ramalingam;Lancet Oncol,2014
5. P76.78 Evaluation of the development of brain metastases in patients treated with dacomitinib or gefitinib from ARCHER 1050 study;Zhou;J Thorac Oncol,2021